Immunocore appoints Bahija Jallal as CEO

Immunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board.

Bahija Jallal joins from AstraZeneca where she was President and head of its global biologics research and development unit, MedImmune. She was a member of the senior executive team at AstraZeneca reporting to the CEO.  During her time at MedImmune, she oversaw significant growth in the AstraZeneca biologics pipeline across a range of disease areas.

“Bahija Jallal’s appointment as CEO of Immunocore strengthens the company’s  management team and signals that it is entering a period of significant clinical and commercial maturity,” said Jean-Michel Cossery, Non-Executive Director of Malin and Malin’s Immunocore Board designate.

Malin owns approximately 10% of Immunocore and carried its investment in Immunocore at €85.1 million at 30 June 2018 in its portfolio fair value estimateunder International Private Equity Valuation guidelines.